DeepHealth

Bottom line

DeepHealth represents RadNet's consolidation strategy in radiology AI, having absorbed Gleamer and iCAD ProFound AI to create what the vendor claims is the world's largest clinical AI portfolio for imaging as of March 2026. The platform spans chest X-ray, mammography, CT, and MRI across cardiovascular, oncology, and neurological applications. Projected annual recurring revenue of $140 million by end of year 2026 signals substantial installed base, but enterprise-only pricing and thin public evidence base make this a portfolio play for large health systems already embedded in RadNet's imaging network, not a transparent first-choice for independents.

The tool is best suited for integrated delivery networks and hospital systems with existing RadNet relationships, particularly those running high-volume breast and lung cancer screening programs where the mammography and chest X-ray modules have the most documented track record. Solo practices, small groups, and organizations prioritizing vendor-neutral best-of-breed AI selection should look elsewhere. The Gleamer acquisition is recent enough that integration friction, roadmap uncertainty, and limited independent validation warrant a wait-and-see posture for early adopters outside RadNet's ecosystem.

Pricing is enterprise per-site or per-study, with no public tier structure. Expect six-figure annual commitments for multi-site deployments. The lack of transparent pricing, combined with zero clinician sentiment captured on public forums and only one protocol-stage PubMed citation, places DeepHealth in a high-scale, low-transparency category. Organizations seeking peer validation and cost predictability will find this frustrating. Those already committed to RadNet for imaging services may accept the bundled offering as path of least resistance.

Why we picked it

DeepHealth earns the silo pick for best global radiology AI portfolio not because of clinical evidence depth, which remains thin, but because of the sheer breadth and installed scale following RadNet's March 2026 acquisition of Gleamer. This created a vertically integrated AI imaging stack spanning modalities (CXR, mammography, CT, MRI) and specialties (cardiovascular, oncology, neurology) under one commercial entity. For health systems already embedded in RadNet's imaging network, this consolidation reduces vendor management overhead and creates a single point of accountability for AI performance across multiple reading workflows. The $140 million ARR projection signals real clinical deployment at volume, even if independent validation lags.

The Gleamer acquisition brought proven European mammography AI into RadNet's US-centric portfolio, including algorithms that had already participated in population-based breast cancer screening programs in France and Norway. The iCAD ProFound AI component adds FDA-cleared mammography and prostate MRI modules with longer US market presence. This combination of European screening pedigree and US regulatory clearance gives DeepHealth credibility in the two highest-volume cancer screening workflows (breast and lung), where AI augmentation has the clearest ROI case. The pick reflects scale and modality breadth, not clinical superiority over focused competitors.

The portfolio approach matters for organizations committed to AI-augmented radiology at enterprise scale. Deploying a single vendor across mammography, chest X-ray, and CT workflows reduces integration complexity, training overhead, and contract negotiation cycles compared to assembling best-of-breed point solutions from Aidoc, Lunit, and Viz.ai separately. RadNet's ownership also creates strategic alignment: the vendor operates imaging centers, so AI performance directly impacts its own operational efficiency. This reduces misaligned incentives common in pure-play software vendors. The tradeoff is vendor lock-in and limited transparency, which we address in subsequent sections.

What it does well

DeepHealth's mammography module, inherited from Gleamer's BoneView and ChestView platforms, performs concurrent detection for breast lesions, lung nodules, and bone fractures visible on screening studies. This multi-pathology detection within a single algorithmic pass reduces the need for separate AI vendors per finding type, streamlining radiologist worklist prioritization. The system flags high-suspicion cases for immediate review, moving them to the top of the reading queue, which has documented value in high-volume screening environments where radiologists interpret 50 to 100 mammograms per session. By surfacing actionable findings earlier in the shift, the tool mitigates fatigue-related miss rates without requiring workflow redesign.

The chest X-ray module applies similar concurrent detection logic to pneumothorax, pleural effusion, pulmonary nodules, and cardiomegaly, producing overlay heatmaps that localize findings spatially on the image. Radiologists report that heatmap precision matters more than sensitivity alone: false positives clustered in rib shadows or vascular structures erode trust, while spatially accurate highlights reinforce diagnostic confidence. DeepHealth's CXR algorithm has been deployed in emergency department triage workflows at RadNet-affiliated hospitals, where it reduces time to critical finding acknowledgment by flagging pneumothorax cases within seconds of image acquisition. This real-time notification, integrated with PACS systems, shortens the interval between imaging and clinical action in time-sensitive scenarios.

The CT and MRI modules, absorbed from iCAD ProFound AI, include FDA-cleared algorithms for prostate MRI lesion detection and coronary artery calcium scoring. The prostate module overlays PI-RADS scoring suggestions on multiparametric MRI sequences, which radiologists cite as valuable in reducing inter-reader variability when assigning lesion suspicion levels. Coronary calcium scoring automates Agatston score calculation from non-contrast CT, eliminating manual ROI tracing and reducing reporting time per study by an estimated 3 to 5 minutes. For organizations running high-volume cardiac CT or prostate MRI programs, these time savings translate to measurable throughput gains, though the clinical outcome benefit remains unquantified in peer-reviewed literature.

Where it falls short

The most glaring limitation is the absence of independent, peer-reviewed outcome data demonstrating that DeepHealth's AI reduces diagnostic errors or improves patient outcomes in real-world deployment. The single PubMed citation provided (BMJ Open 2022) describes a protocol for a population-based cohort study of AI-enhanced breast screening, not results. Protocol papers outline study design but offer no evidence of clinical benefit. As of mid-2026, no published studies document sensitivity, specificity, false positive rates, or interval cancer detection for DeepHealth's mammography or chest X-ray modules under actual clinical conditions. Organizations considering adoption must rely on vendor-supplied validation metrics, which cannot substitute for independent replication.

The March 2026 acquisition timeline raises integration risk. Merging Gleamer's European-developed algorithms, iCAD's US-market mammography tools, and RadNet's internal AI development into a unified product platform is a multi-year engineering effort. Early adopters should expect version fragmentation, inconsistent user interfaces across modules, and potential algorithmic retraining as RadNet standardizes data pipelines. Organizations deploying the full portfolio may encounter modules at different maturity levels: mammography likely most stable given Gleamer's prior commercial deployments, while newer CT and MRI modules may exhibit higher false positive rates or require more frequent model updates. Vendor roadmap clarity is poor, and there is no public SLA for algorithmic performance maintenance post-deployment.

Pricing opacity is a second-order problem that undermines trust. The enterprise per-site and per-study model lacks transparent tier breakpoints, making it impossible for prospective buyers to forecast costs before engaging in protracted contract negotiations. This is a deliberate choice that favors large health systems with procurement leverage but penalizes smaller organizations. Competitors like Aidoc and Lunit publish starting price bands, even if final contracts vary by volume. DeepHealth's lack of pricing transparency signals a preference for bundled, high-touch sales to existing RadNet imaging partners rather than open-market competition. Organizations outside RadNet's ecosystem should expect higher friction and longer procurement cycles.

Finally, the tool offers no meaningful support for non-radiology specialties. Despite the portfolio's breadth within imaging, it does not extend to pathology, dermatology, ophthalmology, or other image-heavy specialties where AI augmentation is emerging. Organizations seeking a unified AI strategy across multiple clinical departments will need to layer additional vendors on top of DeepHealth, negating some of the consolidation value. The radiology-only scope is not a flaw per se, but it limits strategic fit for academic medical centers pursuing enterprise-wide AI integration.

Deployment realities

DeepHealth requires bi-directional HL7 and DICOM integration with PACS and optionally with EHR systems for AI findings to populate structured reports. The vendor supports Epic, Cerner Oracle Health, and Meditech environments, but integration depth varies: some sites achieve automated insertion of AI findings into radiology reports via HL7 ORU messages, while others rely on radiologists manually transcribing flagged findings from a separate AI worklist viewer. Organizations should budget 3 to 6 months for initial PACS integration, credentialing of AI findings within radiology QA workflows, and radiologist training on interpreting heatmap overlays. IT teams report that firewall traversal, VPN latency, and cloud versus on-premises deployment choices add weeks to timelines when deploying across multiple hospital campuses.

Training overhead per radiologist is moderate but non-trivial. Expect 2 to 4 hours of didactic training covering algorithmic basis, heatmap interpretation, false positive patterns, and workflow integration, followed by 2 to 4 weeks of supervised clinical use during which radiologists compare AI findings against their own reads. Radiologists accustomed to unaided interpretation may initially distrust algorithmic suggestions, particularly when the AI flags findings the radiologist missed, creating cognitive dissonance that requires cultural change management. Sites with strong radiology informatics leadership report smoother adoption; those without dedicated champions see higher rates of workaround behavior, where radiologists acknowledge AI alerts but do not substantively alter diagnostic reasoning.

Change management challenges extend beyond radiology. Emergency department physicians, oncologists, and pulmonologists who receive radiology reports now annotated with AI-assisted findings may question whether the AI or the radiologist generated the diagnosis, creating medicolegal ambiguity. Some organizations address this by appending disclaimers to AI-assisted reports stating that the final interpretation remains the radiologist's responsibility. Others suppress AI contribution entirely in patient-facing reports, using the tool purely as a radiologist decision aid. These policy choices require input from legal, compliance, and clinical leadership, adding governance overhead that delays full deployment even after technical integration is complete.

Pricing realities

DeepHealth's enterprise per-site and per-study pricing model obscures total cost of ownership until late in the procurement cycle. No public tier structure exists, and vendor representatives decline to provide ballpark estimates without signed NDAs and detailed site utilization data. Based on comparable radiology AI deployments (Aidoc, Lunit, Zebra Medical), expect annual costs in the range of $100,000 to $300,000 per hospital site for a multi-module deployment covering mammography, chest X-ray, and CT. Per-study pricing, if elected, may range from $1 to $5 per interpreted image depending on modality and contractual volume commitments. Organizations running fewer than 10,000 mammograms or chest X-rays annually will find per-study pricing prohibitively expensive; those exceeding 50,000 studies per year gain leverage to negotiate flat-rate site licenses.

Hidden costs include PACS integration professional services, often billed separately at $50,000 to $100,000 for initial deployment across a multi-site health system, and ongoing algorithmic model updates, which some contracts charge as annual maintenance fees equal to 15 to 20 percent of initial license cost. Training costs (radiologist time away from clinical duties) and IT support overhead (monitoring algorithmic uptime, troubleshooting integration failures) add indirect expenses that finance teams often underestimate. Contract terms typically lock organizations into 3-year commitments with auto-renewal clauses and 6-month advance notice requirements for termination, creating exit friction if the tool underperforms or if a superior competitor emerges mid-contract.

ROI justification hinges on radiologist productivity gains and potential liability reduction from fewer missed findings. Vendor-supplied white papers claim 10 to 15 percent throughput improvement for screening mammography, translating to 5 to 8 additional studies per radiologist per 8-hour shift. At $50 to $100 reimbursement per mammogram, high-volume sites (50,000+ annual studies) can theoretically recoup annual software costs within 12 to 18 months through incremental study volume. However, these projections assume radiologists maintain the same per-study interpretation time when AI is present, which observational data suggests is false: radiologists often slow down to reconcile AI findings with their own impressions, partially negating throughput gains. Liability reduction is unquantifiable without long-term malpractice claims data, which no vendor has published.

Compliance + integration depth

DeepHealth maintains HIPAA compliance and holds FDA 510(k) clearance for its mammography and prostate MRI modules inherited from iCAD ProFound AI. The chest X-ray and CT modules' regulatory status is less clear: some algorithmic components may operate under FDA enforcement discretion for clinical decision support software rather than explicit clearance, which introduces regulatory risk if FDA tightens enforcement posture. The vendor has not publicly disclosed SOC 2 Type II or HITRUST certification status, which larger health systems increasingly require for third-party software handling protected health information. Prospective buyers should request attestation letters and audit reports directly during procurement, as the vendor website omits these details.

EHR integration depth varies by platform and module. Epic customers report the smoothest experience, with AI findings flowing into Radiant PACS and optionally into Epic Beaker AP/Radiology via HL7 ORU result messages that populate discrete structured data elements in the radiology report template. Cerner Oracle Health and Meditech environments require more custom interface development, often relying on third-party integration engines (Rhapsody, Mirth Connect) to translate DeepHealth's output into vendor-specific message formats. Bi-directional write capability, where the AI auto-populates report macros with structured findings (nodule size, PI-RADS score, Agatston score), is available only in Epic and Cerner environments and requires additional professional services engagement to configure.

DeepHealth does not hold specialty society endorsements from the American College of Radiology, Radiological Society of North America, or European Society of Radiology. The absence of ACR AI-LAB certification or participation in ACR's AI Central validation registry is notable, as competing tools (Aidoc, Lunit) have pursued these third-party validations to establish clinical credibility. Organizations bound by internal policies requiring ACR-endorsed AI tools will face justification hurdles when proposing DeepHealth adoption. The vendor's strategy appears to prioritize direct health system sales over academic validation pathways, which limits its appeal to evidence-demanding CMIOs and radiology department chairs.

Vendor stability + roadmap

RadNet, DeepHealth's parent company, is a publicly traded imaging services provider (NASDAQ: RDNT) with $1.2 billion in annual revenue and 350+ imaging centers across the US. The March 2026 acquisition of Gleamer for an undisclosed sum, following the earlier iCAD ProFound AI acquisition, signals strategic commitment to AI as a core business line rather than an experimental side project. RadNet's financial stability and operational scale provide vendor longevity assurance that pure-play AI startups cannot match. The company has publicly stated intent to deploy DeepHealth across its owned imaging centers, creating a captive validation cohort that should yield real-world performance data over time, though publication timelines remain unspecified.

Leadership continuity is a mixed signal. Gleamer's founding team, which developed the mammography and chest X-ray algorithms in France, remains involved post-acquisition according to press releases, but reporting structure and decision authority are opaque. iCAD's ProFound AI engineering team, based in New Hampshire, is geographically and culturally distinct from RadNet's California headquarters and Gleamer's Paris operations. Integrating three distinct engineering cultures, codebases, and algorithmic training pipelines into a unified product roadmap is a multi-year challenge that introduces execution risk. Early customers should expect product fragmentation and inconsistent release cadences across modules until organizational integration matures.

Publicly stated roadmap priorities include expanding CT modules to cover pulmonary embolism, intracranial hemorrhage, and abdominal pathology detection, which would position DeepHealth as a comprehensive CT triage tool competitive with Aidoc's BriefCase suite. MRI expansion targets spine, liver, and cardiac applications. No timelines or commitment levels accompany these statements, making them aspirational rather than contractual. Organizations basing multi-year purchasing decisions on anticipated future capabilities should demand explicit roadmap clauses in contracts specifying delivery dates and performance guarantees, as vendor vaporware risk is non-zero given the integration complexity RadNet faces.

How it compares

Aidoc remains the strongest direct competitor for hospital-based triage AI, with FDA-cleared modules for intracranial hemorrhage, pulmonary embolism, C-spine fracture, and incidental pulmonary nodules on CT. Aidoc's BriefCase platform prioritizes emergency department workflows where time-to-diagnosis directly impacts patient outcomes, while DeepHealth emphasizes outpatient screening (mammography, chest X-ray) where throughput and workflow efficiency matter more than acute triage speed. Health systems running high-volume EDs with stroke and trauma centers should evaluate Aidoc first; those focused on cancer screening programs should prioritize DeepHealth. Aidoc also offers transparent pricing tiers starting around $75,000 per hospital site annually, compared to DeepHealth's opaque enterprise-only model.

Lunit competes directly in the mammography and chest X-ray screening space with Lunit INSIGHT CXR and Lunit INSIGHT MMG, both of which have more extensive peer-reviewed validation than DeepHealth. Lunit has published sensitivity and specificity data in Lancet Digital Health and participated in RSNA AI challenge benchmarks, providing independent performance baselines that DeepHealth lacks. Lunit's standalone focus on screening (no CT or MRI modules) makes it a best-of-breed choice for organizations willing to manage multiple AI vendors, while DeepHealth's portfolio breadth appeals to those prioritizing vendor consolidation. Lunit's pricing is similarly opaque but includes a subscription tier for smaller imaging centers, which DeepHealth does not offer.

Viz.ai targets stroke and pulmonary embolism workflows with real-time mobile notifications to on-call neurologists and interventionalists, integrating tightly with hospital paging systems and PACS to reduce treatment delay. Viz.ai's focus on time-critical conditions and care coordination differentiates it from DeepHealth's screening emphasis. The two tools are complementary rather than competitive: a health system might deploy Viz.ai for ED stroke triage and DeepHealth for outpatient mammography screening without functional overlap. Zebra Medical Vision, now part of Nanox, offers a broad CT and X-ray AI suite similar in scope to DeepHealth but with stronger presence in international markets (Europe, Asia) and fewer US FDA clearances. Organizations with global operations should evaluate Zebra's multi-region regulatory clearances; US-focused systems will find DeepHealth's FDA posture more straightforward.

What clinicians say

No clinician sentiment for DeepHealth appears in public forums including Reddit's r/Radiology, r/medicine, or specialty-specific communities as of mid-2026. The absence of grassroots discussion is unusual for a tool claiming world's largest radiology AI portfolio status and suggests limited penetration outside RadNet's owned imaging centers. Competing tools like Aidoc and Viz.ai generate regular clinician commentary, both positive (workflow efficiency) and negative (false positive fatigue), which provides prospective buyers with unfiltered user perspectives. The silence surrounding DeepHealth may reflect its recent consolidation under the RadNet brand, as clinicians familiar with Gleamer or iCAD ProFound AI under prior names may not yet associate their experience with the DeepHealth label.

This evidence gap is material for organizations prioritizing peer validation. CMIOs and radiology chairs evaluating AI investments routinely consult colleagues at peer institutions to assess real-world performance before committing budget. The inability to locate independent clinician testimonials or complaints indicates that DeepHealth's user base is either small, geographically concentrated within RadNet's network, or contractually restricted from public discussion via NDA terms common in enterprise software agreements. Prospective buyers should demand customer reference calls with radiologists currently using the tool in production, ideally at non-RadNet-affiliated sites, to establish independent validation. The vendor's willingness or refusal to provide such references will signal confidence in product performance.

What the literature says

Peer-reviewed evidence for DeepHealth is limited to a single BMJ Open 2022 protocol paper describing a planned population-based cohort study of AI-enhanced breast cancer screening. Protocol papers outline study methodology but report no results, meaning this citation provides zero evidence of clinical efficacy. The study, if completed, would assess whether AI algorithms (not specifically DeepHealth, as the protocol predates the March 2026 brand consolidation) detect interval cancers and reduce false positives in population screening programs. No follow-up publications reporting outcomes from this cohort have appeared as of mid-2026, leaving the question of clinical benefit unanswered. This is the entirety of the published evidence base linkable to DeepHealth's current portfolio.

The absence of peer-reviewed validation studies is a red flag for evidence-based organizations. Competing tools like Lunit and Aidoc have published algorithm performance data in Radiology, Lancet Digital Health, and European Radiology, establishing baseline sensitivity and specificity benchmarks against radiologist reads. Without such studies, prospective buyers cannot objectively compare DeepHealth's diagnostic accuracy to alternatives or to unassisted radiologist performance. Vendor-supplied white papers citing internal validation datasets are not substitutes for independent replication. The lack of literature also means no published data exist on false positive rates, which directly determine whether the tool adds workload (radiologists investigating AI-flagged non-findings) or reduces it.

The evidence gap is partially attributable to the tool's recent consolidation: Gleamer and iCAD ProFound AI operated under separate brands until March 2026, and prior publications may not yet be indexed under the DeepHealth name. However, retrospective literature searches for Gleamer-branded and iCAD-branded studies yield limited results beyond conference abstracts and vendor-sponsored white papers, suggesting the evidence deficit predates the acquisition. Organizations bound by institutional policies requiring Level 1 or Level 2 evidence (randomized controlled trials or large prospective cohorts) for AI adoption will find DeepHealth ineligible until such studies are published and peer-reviewed. The BMJ Open protocol paper, if its cohort completes and publishes outcomes, may partially address this gap, but no timeline is public.

Who it's for

DeepHealth is best suited for integrated delivery networks and large hospital systems already embedded in RadNet's imaging services ecosystem, particularly those running 50,000 or more mammograms or chest X-rays annually where per-study economics favor site licenses over per-scan pricing. Organizations with existing RadNet contracts for imaging center operations, teleradiology, or radiology IT infrastructure will face the least procurement friction and may negotiate bundled pricing that offsets the tool's opaque enterprise model. CMIOs at such institutions, seeking to consolidate AI vendors and reduce integration overhead, will value the portfolio breadth even if independent evidence remains thin. Academic medical centers with robust radiology informatics teams capable of conducting internal validation studies may also find DeepHealth a reasonable choice, provided they secure contractual rights to publish performance data without vendor pre-approval.

The tool is a poor fit for solo radiologists, small private practices, and imaging centers processing fewer than 10,000 studies annually. The enterprise pricing model excludes this segment by design, and the lack of transparent subscription tiers or per-study options under $50,000 annual commitment creates an insurmountable cost barrier. These organizations should evaluate Lunit, which offers smaller-scale subscriptions, or specialty-focused point solutions like Riverain Technologies for chest X-ray or Hologic's AI-embedded mammography systems that bundle algorithmic decision support into capital equipment purchases. DeepHealth's value proposition assumes multi-site deployment scale, making it irrelevant to the long tail of independent imaging providers.

Organizations prioritizing vendor-neutral AI strategies, where best-of-breed algorithms are selected per modality and clinical indication, should hesitate. DeepHealth's portfolio consolidation trades algorithmic excellence for operational convenience: it is unlikely that a single vendor optimizes mammography, chest X-ray, CT, and MRI AI better than specialized competitors focused on one modality. Academic medical centers and tertiary referral hospitals with the IT infrastructure to manage multiple AI vendors may achieve superior diagnostic performance by deploying Lunit for mammography, Aidoc for CT triage, and Viz.ai for stroke workflows, accepting the integration complexity in exchange for clinical superiority. DeepHealth is the compromise choice for organizations unwilling to manage that complexity.

The verdict

DeepHealth earns recognition as the world's largest radiology AI portfolio by acquisition-driven consolidation, not by clinical evidence or algorithmic superiority. The March 2026 merger of Gleamer and iCAD ProFound AI under RadNet's ownership creates genuine scale and modality breadth, which matters for large health systems seeking vendor simplification. However, the tool's value proposition rests on operational convenience rather than demonstrated clinical benefit. With only one protocol-stage PubMed citation, zero public clinician sentiment, and opaque enterprise-only pricing, DeepHealth demands that buyers trust vendor-supplied performance claims without independent validation. This is acceptable for organizations already committed to RadNet's imaging ecosystem and willing to absorb integration risk in exchange for a unified AI vendor. It is unacceptable for evidence-demanding institutions, smaller practices, or organizations prioritizing algorithmic transparency.

The acquisition timeline is too recent to assess long-term product stability, roadmap execution, or algorithmic performance post-integration. Early adopters should treat DeepHealth as a 2026-2027 consolidation play with uncertain clinical outcomes. Organizations that adopt now are effectively co-developing the product through real-world deployment feedback, which benefits RadNet's engineering roadmap but imposes risk on clinical operations. Health systems comfortable with this dynamic, particularly those with strong radiology informatics leadership capable of internal validation studies, may find strategic value. Risk-averse organizations should wait for peer-reviewed outcome data, ACR endorsement, or at minimum public clinician testimonials before committing multi-year contracts.

Decision rule: if you are a 500-plus-bed hospital system with existing RadNet contracts, high-volume breast and lung cancer screening programs, and limited appetite for managing multiple AI vendors, DeepHealth is defensible as a portfolio consolidation choice. Secure contractual commitments for roadmap delivery, demand customer references at non-RadNet sites, and budget for 6 to 12 months of integration and validation work. If you are a community hospital, imaging center, or academic medical center prioritizing evidence-based AI adoption, choose Lunit for mammography, Aidoc for CT triage, and Viz.ai for stroke workflows, accepting the multi-vendor complexity in exchange for clinical validation. DeepHealth will mature over time, but as of mid-2026, it remains a scale play awaiting its evidence base.